Evidence map›Paper›PMID 25171482›Full record

ArticlePloS one2014

Oxymatrine improves intestinal epithelial barrier function involving NF-κB-mediated signaling pathway in CCl4-induced cirrhotic rats.

Jian-Bo Wen, Fang-Qing Zhu, Wei-Guo Chen, Li-Ping Jiang, Jie Chen, Zhao-Peng Hu, Yong-Jian Huang, Zhi-Wei Zhou, Gui-Liang Wang, Hao Lin and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Frontiers in pharmacology · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jian-Bo WenDepartment of Gastroenterology, the Affiliated Pingxiang Hospital of Southern Medical University, Pingxiang, Jiangxi, China.
Fang-Qing ZhuDepartment of Gastroenterology, the Affiliated Pingxiang Hospital of Southern Medical University, Pingxiang, Jiangxi, China.
Wei-Guo ChenDepartment of Gastroenterology, the Affiliated Pingxiang Hospital of Southern Medical University, Pingxiang, Jiangxi, China.
Li-Ping JiangAnimal Laboratory, the Affiliated Pingxiang Hospital of Southern Medical University, Pingxiang, Jiangxi, China.
Jie ChenDepartment of Pharmacology, the Affiliated Pingxiang Hospital of Southern Medical University, Pingxiang, Jiangxi, China.
Zhao-Peng HuDepartment of Pathology, the Affiliated Pingxiang Hospital of Southern Medical University, Pingxiang, Jiangxi, China.
Yong-Jian HuangDepartment of Clinical Laboratory, the Affiliated Pingxiang Hospital of Southern Medical University, Pingxiang, Jiangxi, China.
Zhi-Wei ZhouDepartment of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, Florida, United States of America.
Gui-Liang WangDepartment of Gastroenterology, the Affiliated Pingxiang Hospital of Southern Medical University, Pingxiang, Jiangxi, China.
Hao LinDepartment of Gastroenterology, the Affiliated Pingxiang Hospital of Southern Medical University, Pingxiang, Jiangxi, China.
Shu-Feng ZhouDepartment of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, Florida, United States of America.
Southern Medical University · CNUniversity of South Florida · USPingxiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence suggests that intestinal epithelial barrier dysfunction plays an important role in the pathogenesis of hepatic cirrhosis and its complications such as gastrointestinal injury and hepatic encephalopathy. To date, there is no cure for cirrhosis-associated intestinal mucosal lesion and ulcer. This study aimed to investigate the effect of oxymatrine on intestinal epithelial barrier function and the underlying mechanism in carbon tetrachloride (CCl4)-induced cirrhotic rats. Thirty CCl4-induced cirrhotic rats were randomly divided into treatment group, which received oxymatrine treatment (63 mg/kg), and non-treatment group, which received the same dose of 5% glucose solution (vehicle). The blank group (n = 10 healthy rats) received no treatment. Terminal ileal samples were collected for histopathological examination. The expression level of nuclear factor-κB (NF-κB) p65 in ileal tissue was evaluated by immunohistochemistry. The gene and protein expression levels of tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6) in ileal tissues were analyzed by reverse-transcriptase polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. Additionally, plasma endotoxin level was determined. In comparison to the blank group, a significant alteration in the morphology of intestinal mucosal villi in the non-treatment group was observed. The intestinal mucosal villi were atrophic, shorter, and fractured, and inflammatory cells were infiltrated into the lamina propria and muscular layer. Besides, serious swell of villi and loose structure of mucous membrane were observed. Oxymatrine reversed the CCl4-induced histological changes and restored intestinal barrier integrity. Moreover, oxymatrine reduced the protein expression level of NF-κB p65, TNF-α, and IL-6, which were elevated in the vehicle-treated group. In addition, the serum endotoxin level was significantly decreased after oxymatrine treatment in CCl4-induced cirrhotic rats. The results indicate that oxymatrine improves intestinal barrier function via NF-κB-mediated signaling pathway and may be used as a new protecting agent for cirrhosis-associated intestinal mucosal damage.

Indexed as

AlkaloidsAnimalsCarbon TetrachlorideEndotoxinsEnzyme-Linked Immunosorbent AssayGene ExpressionImmunohistochemistryInterleukin-6Intestinal MucosaIntestinesLiver CirrhosisMaleMatrinesProtective AgentsQuinolizinesRandom AllocationAlkaloidsCarbon TetrachlorideEndotoxinsInterleukin-6MatrinesoxymatrineProtective AgentsQuinolizinesTranscription Factor RelATumor Necrosis Factor-alpha

Identifiers

PMID25171482
PMCPMC4149463
OpenAlexW2092753017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.